Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390625 | 1.00 | MIF (0.50) | MIFGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3525214 | 0.87 | ESR1 (0.44) | MIFCYP2C19HIF1AMEN1KMT2A | |
| SCHEMBL6647551 | 0.86 | CYP2C19 (0.56) | CYP2C19HIF1AKMT2AMAPTALDH1A1 | |
| SCHEMBL6464415 | 0.86 | CYP2C19 (0.56) | CYP2C19HIF1AKMT2AMAPTALDH1A1 | |
| SCHEMBL27823794 | 0.86 | CYP2C19 (0.56) | CYP2C19HIF1AKMT2AMAPTALDH1A1 | |
| SCHEMBL27658141 | 0.86 | CYP3A4 (0.41) | MIFGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1147458 | 0.85 | CYP2C19 (0.40) | CYP2C19HIF1AMEN1KMT2AMAPT | |
| SCHEMBL1147854 | 0.85 | CYP2C19 (0.40) | CYP2C19HIF1AMEN1KMT2AMAPT | |
| SCHEMBL27573423 | 0.85 | CYP2C19 (0.40) | MIFCYP2C19HIF1AMEN1KMT2A | |
| SCHEMBL6946381 | 0.84 | CYP2C19 (0.46) | CYP2C19HIF1AKMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1816913-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006091246-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-31 | — | — | WO | claimed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | claimed |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-7947682-B2 | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008090357-A2 | N, N; -SUBSTITUTED PIPERAZINES BINDING TO MELANOCORTIN RECEPTOR | PALATIN TECHNOLOGIES, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1816913-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
| WO-2006091246-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | MIF 3474/4885GRIN2D 4546/4885GRIN3B 2903/4885 |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, LIPG | MIF 3474/4885GRIN2D 4546/4885GRIN3B 2903/4885 |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | MIF 3344/4885GRIN2D 4639/4885GRIN3B 3380/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | MIF 3344/4885GRIN2D 4639/4885GRIN3B 3380/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | MIF 3344/4885GRIN2D 4639/4885GRIN3B 3380/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | MIF 3344/4885GRIN2D 4639/4885GRIN3B 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.